Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass

OBJECTIVE: Roux-en-Y gastric bypass is an effective intervention for metabolic disorder. We aim to elucidate whether ghrelin contributes to weight reduction, and glycemic and lipid control after Roux-en-Y gastric bypass (RYGB). DESIGN: Four-week-old WT and Ghrl-TSC1(-/-) mice were fed high fat diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yuan, Yu, Ruili, He, Rui, Sun, Lijun, Luo, Chao, Feng, Lu, Chen, Hong, Yin, Yue, Zhang, Weizhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445200/
https://www.ncbi.nlm.nih.gov/pubmed/36082078
http://dx.doi.org/10.3389/fendo.2022.891379
Descripción
Sumario:OBJECTIVE: Roux-en-Y gastric bypass is an effective intervention for metabolic disorder. We aim to elucidate whether ghrelin contributes to weight reduction, and glycemic and lipid control after Roux-en-Y gastric bypass (RYGB). DESIGN: Four-week-old WT and Ghrl-TSC1(-/-) mice were fed high fat diet for 12 weeks before surgery, and continued to be on the same diet for 3 weeks after surgery. Body weight, food intake, glycemic and lipid metabolism were analyzed before and after surgery. RESULTS: Gastric and circulating ghrelin was significantly increased in mice with RYGB surgery. Hypoghrelinemia elicited by deletion of TSC1 to activate mTOR signaling in gastric X/A like cells demonstrated no effect on weight reduction, glycemic and lipid control induced by Roux-en-Y gastric bypass surgery. CONCLUSION: Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.

Ejemplares similares